CHEN THOMAS C purchased $40K of NTHI (indirect holdings)

CHEN THOMAS C (CEO) purchased 10,798 indirectly-held shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at an average of $3.70 ($3.60–$3.82) across 2 trades over 2026-09-11 to 2026-09-14.

Original reporting
SEC EDGAR · CHEN THOMAS C
Published Sep 16, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTHI
Neutral
low confidence
Mentioned
$NTHI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHINeutralLow
01

Why it matters

The purchase is modest and unlikely to affect market perception.

02

Market read

Minor insider activity with low trading relevance.

03

What to watch

Potential upcoming financing or partnership not reflected in the filing.

Relevance 4/10Novelty 2/10Timing: post‑market filing on 2026‑09‑15

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$NTHINeutralLow confidence
Context

CEO Chen Thomas C bought 10,798 shares for $39,999.83 via open‑market trades.

Expected impact

Minimal short‑term impact; unlikely to move price materially.

Evidence & confidence

Purchase amount (~$40K) is small relative to market cap; typical for 10b5‑1 plans.

Market effects

No immediate sector impact; insider activity is company‑specific.

Limited to US micro‑cap market where NTHI trades.

None

Counterpoint

Even a small insider buy could hint undisclosed positive news.

Key entities

  • Neonc Technologies Holdings, Inc.

    Issuer of the Form 4 filing.

  • Chen Thomas C

    CEO and 10% owner of NTHI.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTHIMedAI 8/10

NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data to be presented at the Society for Neuro-Oncology Annual Meeting on November 13 CALABASAS, Calif., Nov.

$NTHIMedAI 8/10

NeOnc to Present NEO100 and NEO212 Data at Neuro-Oncology Meeting

NeOnc Technologies (NTHI) will present data on its NEO100 and NEO212 programs at the Society for Neuro-Oncology meeting. NEO100 data includes Phase 1/2a study and compassionate use results for recurrent IDH1-mutant astrocytoma. NEO212 data covers Phase 1 safety, pharmacokinetics, and early activity signals in TMZ-resistant recurrent GBM and brain metastases. Both posters are scheduled for November 13, 2026.

$NTHILowAI 8/10

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed movement following initiation of invest